BG Medicine, Inc.

OTCPK:BGMD Stock Report

Market Cap: US$11.0

BG Medicine Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Paul Sohmer

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure11.7yrs
CEO ownershipn/a
Management average tenure11.7yrs
Board average tenure9.7yrs

Recent management updates

No updates

Recent updates

No updates

CEO

Paul Sohmer (75 yo)

11.7yrs

Tenure

US$568,899

Compensation

Dr. Paul R. Sohmer, M.D, has been the Chief Executive Officer, President and Director of BG Medicine, Inc. since May 9, 2013. Dr. Sohmer served as the Chief Executive Officer and President of Viracor-IBT L...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Sohmer
CEO, President & Director11.7yrsUS$568.90kno data
Stephen Hall
CFO, Executive VP & Treasurer11.1yrsUS$448.84kno data
Aram Adourian
Chief Scientific Officer12.3yrsUS$372.81kno data

11.7yrs

Average Tenure

73yo

Average Age

Experienced Management: BGMD's management team is seasoned and experienced (11.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Sohmer
CEO, President & Director11.7yrsUS$568.90kno data
Harry Wilcox
Chairman9.7yrsUS$2.19kno data
Stelios Papadopoulos
Director22yrsUS$2.19kno data
Arnold Levine
Co-Chairman of RDAB Boardno datano datano data
James O'Connor
Director9.2yrsUS$5.48kno data
Jeffrey Luber
Director8.9yrsno datano data
Jeffrey Friedman
Co-Chairman of RDAB Boardno datano datano data
Paul Watkins
Chairperson of LTBS Boardno datano datano data
John Senior
Member of LTBS Boardno datano datano data
Neil Kaplowitz
External Advisor of Ltbs Boardno datano datano data

9.7yrs

Average Tenure

75.5yo

Average Age

Experienced Board: BGMD's board of directors are considered experienced (9.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 10:11
End of Day Share Price 2025/01/08 00:00
Earnings2015/12/31
Annual Earnings2015/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BG Medicine, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Quintin LaiBaird
Kevin DeGeeterLadenburg Thalmann & Company
Stephen UngerLazard Capital Markets